Wire Stories
-
24.8KGlobal Land Survey Equipment Market Forecast to 2028 – Development of Terrestrial Laser Scanners Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Land Survey Equipment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Solution, Industry, Application and Hardware”...
-
30.3KPOTTERY BARN ANNOUNCES GLOBAL COLLABORATION WITH DEEPIKA PADUKONE
Internationally Acclaimed Actor and Global Style Icon Will Collaborate with Pottery Barn as Part of Brand�s International Expansion SAN FRANCISCO–(BUSINESS WIRE)–Pottery Barn,...
-
25.1KQu�bec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement
VANCOUVER, British Columbia–(BUSINESS WIRE)–Qu�bec Nickel Corp. (CSE: QNI) (�Qu�bec Nickel Corp.� or the �Company�) is pleased to announce that it has completed...
-
24.8K
Qu�bec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement
VANCOUVER, British Columbia–(BUSINESS WIRE)–Qu�bec Nickel Corp. (CSE: QNI) (�Qu�bec Nickel Corp.� or the �Company�) is pleased to announce that it has completed...
-
27.4KONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner
Experiences for ONE�s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE–(BUSINESS WIRE)–ONE Championship� (ONE), the world�s largest martial arts...
-
29.6KONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner
Experiences for ONE�s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE–(BUSINESS WIRE)–ONE Championship� (ONE), the world�s largest martial arts...
-
26.3KLooking for a holiday gift? Choose Rokid Air and feel the thrill of carrying a big screen in your pocket
HANGZHOU, China–(BUSINESS WIRE)–The holiday season is back! How do you get your favorite entertainment whenever, wherever? During the holidays, augmented reality glasses...
-
38.8KDatopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Daiichi Sankyo and AstraZeneca�s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile in patients...
-
34.6KDatopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Daiichi Sankyo and AstraZeneca�s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile in patients...
-
28.0KTakeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
? Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology ? Oral Presentations Include Updated Results from Phase...
To Top